Eteplirsen for treating Duchenne muscular dystrophy [ID1003]
In development [GID-HST10007] Expected publication date: TBC
Search results
159 results
-
-
Xpert MTB/RIF assay for the detection of active pulmonary tuberculosis and multi-drug resistant tuberculosis
In development [GID-DT9] Expected publication date: TBC
-
KRAS mutation testing of tumours in adults with metastatic colorectal cancer (discontinued)
In development [GID-DT14] Expected publication date: TBC
-
Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia (DG2)
Both index tests included in this guidance are no longer commercially available. Therefore the guidance has been withdrawn.
-
Diagnosing prostate cancer: PROGENSA PCA3 assay and Prostate Health Index (DG17)
This guideline has been updated and replaced by NICE guideline NG131.
-
Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat (DG10)
This guidance has been updated and replaced by NICE diagnostics guidance 34.
-
Adjunctive colposcopy technologies for examination of the uterine cervix – DySIS and the Niris Imaging System (DG4)
This guidance has been updated and replaced by NICE diagnostics guidance 32.
-
Myocardial infarction (acute): Early rule out using high-sensitivity troponin tests (Elecsys Troponin T high-sensitive, ARCHITECT STAT High Sensitive Troponin-I and AccuTnI+3 assays) (DG15)
This guidance has been updated and replaced by NICE diagnostics guidance 40.
-
Multiple myeloma and related disorders - Freelite assays (and alternative technologies identified during scoping) for diagnosis in primary care
In development [GID-DT28] Expected publication date: TBC